HRP20211492T1 - Liraglutid, namijenjen upotrebi kod kardiovaskularnih stanja - Google Patents
Liraglutid, namijenjen upotrebi kod kardiovaskularnih stanja Download PDFInfo
- Publication number
- HRP20211492T1 HRP20211492T1 HRP20211492TT HRP20211492T HRP20211492T1 HR P20211492 T1 HRP20211492 T1 HR P20211492T1 HR P20211492T T HRP20211492T T HR P20211492TT HR P20211492 T HRP20211492 T HR P20211492T HR P20211492 T1 HRP20211492 T1 HR P20211492T1
- Authority
- HR
- Croatia
- Prior art keywords
- liraglutide
- intended
- accordance
- approximately
- cardiovascular
- Prior art date
Links
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 title claims 21
- 108010019598 Liraglutide Proteins 0.000 title claims 21
- 229960002701 liraglutide Drugs 0.000 title claims 21
- 230000002526 effect on cardiovascular system Effects 0.000 title claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 230000007211 cardiovascular event Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (14)
1. Liraglutid, namijenjen upotrebi u usporavanju razvoja velikog štetnog kardiovaskularnog događaja (MACE) kod ljudskog subjekta koji ima dijabetes tip 2 i kardiovaskularnu bolest, naznačen time što se liraglutid primjenjuje u terapijski djelotvornoj količini na subjektu kojem je to potrebno, te što je navedeni MACE smrt zbog kardiovaskularnog uzroka, nesmrtonosni infarkt miokarda ili nesmrtonosni inzult.
2. Liraglutid, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je navedeni MACE smrt zbog kardiovaskularnog uzroka.
3. Liraglutid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se liraglutid primjenjuje u obliku farmaceutskog pripravka koji sadrži jedno ili više farmaceutski prihvatljivih pomoćnih sredstava.
4. Liraglutid, namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što se navedeni pripravak sastoji od liraglutida i jednog ili više farmaceutski prihvatljivih pomoćnih sredstava.
5. Liraglutid, namijenjen upotrebi u skladu s patentnim zahtjevom 3 ili 4, naznačen time što je farmaceutski pripravak namijenjen primijeni supkutanom injekcijom.
6. Liraglutid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedeni subjekt star najmanje 50 godina.
7. Liraglutid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se na navedenom subjektu primjenjuje kardiovaskularni lijek.
8. Liraglutid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se jedno ili više pomoćnih sredstava bira između puferskog sustava, konzervansa, sredstva za reguliranje toničnosti, kelirajućeg sredstva, stabilizatora, te tenzida.
9. Liraglutid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što farmaceutski pripravak sadrži otprilike 1-20 mg/ml liraglutida, otprilike 2-15 mM fosfatnog pufera, otprilike 2-25 mg/ml propilen-glikola, otprilike 1-18 mg/ml fenola, te ima pH u rasponu od 7,5-9,0.
10. Liraglutid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što farmaceutski pripravak sadrži otprilike 6 mg/ml liraglutida, otprilike 1,42 mg/ml dinatrijevog fosfata dihidrata, otprilike 14,0 mg/ml propilen-glikola, otprilike 5,5 mg/ml fenola, te ima pH od otprilike 8,15.
11. Liraglutid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je farmaceutski pripravak otopina namijenjena injiciranju ručnim injektorom.
12. Liraglutid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je ručni injektor jednokratni ručni injektor od 3 ml.
13. Liraglutid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je farmaceutski pripravak namijenjen primjeni jednom dnevno.
14. Liraglutid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se dnevnu dozu navedenog liraglutida bira iz skupine koju čine 0,6, 1,2, te 1,8 mg.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16158739 | 2016-03-04 | ||
| EP16173917 | 2016-06-10 | ||
| EP16001329 | 2016-06-13 | ||
| US15/401,651 US9968659B2 (en) | 2016-03-04 | 2017-01-09 | Liraglutide in cardiovascular conditions |
| EP17710160.7A EP3423082B1 (en) | 2016-03-04 | 2017-03-03 | Liraglutide in cardiovascular conditions |
| PCT/EP2017/054990 WO2017149112A1 (en) | 2016-03-04 | 2017-03-03 | Liraglutide in cardiovascular conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211492T1 true HRP20211492T1 (hr) | 2021-12-24 |
Family
ID=59723004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211492TT HRP20211492T1 (hr) | 2016-03-04 | 2017-03-03 | Liraglutid, namijenjen upotrebi kod kardiovaskularnih stanja |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9968659B2 (hr) |
| EP (1) | EP3423082B1 (hr) |
| JP (1) | JP6940512B2 (hr) |
| KR (1) | KR102417455B1 (hr) |
| CN (2) | CN108778317A (hr) |
| AU (2) | AU2017225841A1 (hr) |
| BR (1) | BR112018067344A2 (hr) |
| CA (1) | CA3013532C (hr) |
| CL (1) | CL2018002515A1 (hr) |
| DK (1) | DK3423082T5 (hr) |
| ES (1) | ES2893755T3 (hr) |
| HR (1) | HRP20211492T1 (hr) |
| HU (1) | HUE055844T2 (hr) |
| IL (1) | IL261169B (hr) |
| MA (1) | MA43704A (hr) |
| MX (1) | MX2018010097A (hr) |
| MY (1) | MY195657A (hr) |
| PH (1) | PH12018501844A1 (hr) |
| PL (1) | PL3423082T3 (hr) |
| RS (1) | RS62501B1 (hr) |
| RU (1) | RU2745604C2 (hr) |
| SI (1) | SI3423082T1 (hr) |
| WO (1) | WO2017149112A1 (hr) |
| ZA (1) | ZA201805538B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
| CA3056663C (en) | 2019-04-05 | 2022-10-18 | Jeffrey S. RIESMEYER | Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus |
| JP2024500410A (ja) * | 2020-12-16 | 2024-01-09 | ザ チャイニーズ ユニバーシティー オブ ホンコン | 老化脳機能低下を逆転する方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5808203A (en) | 1997-05-12 | 1998-09-15 | Medrad, Inc. | Fluid pressure measurement devices |
| WO2003084563A1 (en) | 2002-04-04 | 2003-10-16 | Novo Nordisk A/S | Glp-1 agonist and cardiovascular complications |
| KR101243648B1 (ko) * | 2003-11-20 | 2013-03-14 | 노보 노르디스크 에이/에스 | 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제 |
| CN112618700A (zh) * | 2004-11-12 | 2021-04-09 | 诺和诺德公司 | 促胰岛素肽的稳定制剂 |
| CN101868476B (zh) * | 2007-09-05 | 2015-02-25 | 诺沃-诺迪斯克有限公司 | 胰高血糖素样肽-1衍生物及其制药用途 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| TWI466672B (zh) | 2009-01-29 | 2015-01-01 | Boehringer Ingelheim Int | 小兒科病人糖尿病之治療 |
| MX2011009852A (es) | 2009-03-27 | 2011-09-29 | Bristol Myers Squibb Co | Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv. |
| EP2566502A4 (en) | 2010-05-04 | 2013-10-09 | Glaxosmithkline Llc | METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION |
| KR20230051307A (ko) | 2010-06-24 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| WO2013174768A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada |
| CN103893744B (zh) * | 2012-12-24 | 2017-12-19 | 杭州九源基因工程有限公司 | 一种治疗糖尿病的药物制剂及其制备方法 |
| US20140274889A1 (en) | 2013-03-15 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Cardio- and renoprotective antidiabetic therapy |
| EP3007701A1 (en) | 2013-06-14 | 2016-04-20 | Boehringer Ingelheim International GmbH | Dpp-4 inhibitors for treating diabetes and its complications |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
-
2017
- 2017-01-09 US US15/401,651 patent/US9968659B2/en active Active
- 2017-03-03 KR KR1020187026962A patent/KR102417455B1/ko active IP Right Grant
- 2017-03-03 CN CN201780015266.5A patent/CN108778317A/zh active Pending
- 2017-03-03 EP EP17710160.7A patent/EP3423082B1/en active Active
- 2017-03-03 ES ES17710160T patent/ES2893755T3/es active Active
- 2017-03-03 RU RU2018134061A patent/RU2745604C2/ru active
- 2017-03-03 WO PCT/EP2017/054990 patent/WO2017149112A1/en active Application Filing
- 2017-03-03 DK DK17710160.7T patent/DK3423082T5/da active
- 2017-03-03 JP JP2018546477A patent/JP6940512B2/ja active Active
- 2017-03-03 MY MYPI2018702782A patent/MY195657A/en unknown
- 2017-03-03 MX MX2018010097A patent/MX2018010097A/es unknown
- 2017-03-03 CA CA3013532A patent/CA3013532C/en not_active Expired - Fee Related
- 2017-03-03 HU HUE17710160A patent/HUE055844T2/hu unknown
- 2017-03-03 PL PL17710160T patent/PL3423082T3/pl unknown
- 2017-03-03 CN CN202310320736.6A patent/CN116327897A/zh active Pending
- 2017-03-03 HR HRP20211492TT patent/HRP20211492T1/hr unknown
- 2017-03-03 RS RS20211250A patent/RS62501B1/sr unknown
- 2017-03-03 AU AU2017225841A patent/AU2017225841A1/en not_active Abandoned
- 2017-03-03 BR BR112018067344A patent/BR112018067344A2/pt unknown
- 2017-03-03 SI SI201730917T patent/SI3423082T1/sl unknown
- 2017-03-03 MA MA043704A patent/MA43704A/fr unknown
-
2018
- 2018-04-18 US US15/956,445 patent/US20180236038A1/en not_active Abandoned
- 2018-08-15 IL IL26116918A patent/IL261169B/en unknown
- 2018-08-20 ZA ZA2018/05538A patent/ZA201805538B/en unknown
- 2018-08-30 PH PH12018501844A patent/PH12018501844A1/en unknown
- 2018-09-03 CL CL2018002515A patent/CL2018002515A1/es unknown
-
2024
- 2024-03-26 AU AU2024201937A patent/AU2024201937A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240485T1 (hr) | Pripravci glp-1 i njihova upotreba | |
| ES2508290T3 (es) | Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo | |
| ES2462117T3 (es) | Métodos y composiciones para la administración oral de proteínas | |
| HRP20211492T1 (hr) | Liraglutid, namijenjen upotrebi kod kardiovaskularnih stanja | |
| RU2018119295A (ru) | Фармацевтические составы для местного применения для лечения связанных с воспалением состояний | |
| JP2015038135A5 (hr) | ||
| HRP20110444T1 (hr) | Formulacije paratiroidnih hormona i njihove uporabe | |
| JP2010248207A5 (hr) | ||
| BRPI0213425B8 (pt) | composições injetáveis para a liberação controlada de composto farmacologicamente ativo, usos do referido composto e método para suas preparações | |
| HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
| AR094374A1 (es) | Composiciones y métodos para el tratamiento de trastornos metabólicos | |
| PE20040121A1 (es) | Formulaciones farmaceuticas de liberacion controlada del 5,8,14-triazatetraciclo [10.3.1.02,11.04.9]-hexadeca-2-(11),3,5,7,9-pentaeno | |
| HRP20221150T1 (hr) | Semaglutid u kardiovaskularnim stanjima | |
| CO6260085A2 (es) | Composicion farmaceutica que contiene una combinacion sinergica de venotonicos y vasoprotectores | |
| AR077436A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables. | |
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| CO2019008053A2 (es) | Agente terapéutico para enfermedades del hígado | |
| HRP20201632T1 (hr) | Režimi doziranja melflufena kod raka | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| JP2019507174A5 (hr) | ||
| HRP20240812T1 (hr) | Oblici doziranja i terapijska primjena l-4-klorokinurenina | |
| JP2020510043A5 (hr) | ||
| AR033390A1 (es) | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes | |
| HRP20220896T1 (hr) | Liofilizirana farmaceutska formulacija i njena upotreba | |
| WO2004091541A3 (en) | Methods for the controlled delivery of pharmacologically active compounds |